Cancers, Vol. 16, Pages 1787: Expression of Potential Antibody & ndash;Drug Conjugate Targets in Cervical Cancer

Conclusions: TROP2, CEACAM5 or CD138 do seem suitable for further clinical research and the data presented here might be used to guide further clinical trials with ADCs in advanced and recurrent cervical cancer patients.

Source: Cancers - May 6, 2024 Category: Cancer & Oncology Authors: Michael R. Mallmann Sina Tamir Katharina Alfter Dominik Ratiu Alexander Quaas Christian M. Domroese Tags: Article Source Type: research